Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Sell
12
PRCT Quote, Financials, Valuation and Earnings
Last price:
$29.51
Seasonality move
:
21.08%
Day range:
$29.12 - $30.67
52-week range:
$27.80 - $76.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.34x
P/B ratio:
4.28x
Volume:
1.2M
Avg. volume:
1.1M
1-year change:
-58.17%
Market cap:
$1.6B
Revenue:
$224.5M
EPS (TTM):
-$1.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics Corp.
|
$93.7M | -$0.32 | 37.32% | -7.78% | $50.73 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 227.21% | -28.83% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics Corp.
|
$29.13 | $50.73 | $1.6B | -- | $0.00 | 0% | 5.34x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.7100 | $12.3077 | $201.5M | -- | $0.00 | 0% | 183.75x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.48 | $14.20 | $172.5M | 32.43x | $0.00 | 0% | 1.28x |
|
VNRX
VolitionRX Ltd.
|
$0.28 | $2.20 | $34.6M | -- | $0.00 | 0% | 19.32x |
|
VTAK
Catheter Precision, Inc.
|
$2.30 | -- | $2.8M | 0.40x | $0.00 | 0% | 10.81x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.65 | $1.50 | $91.4M | 64.00x | $0.00 | 0% | 0.71x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics Corp.
|
17.19% | 0.812 | 3.96% | 7.07x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics Corp.
|
$52.4M | -$23.2M | -19.24% | -23.51% | -27.83% | -$9.5M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
PROCEPT BioRobotics Corp. vs. Competitors
-
Which has Higher Returns PRCT or CATX?
Perspective Therapeutics, Inc. has a net margin of -25.7% compared to PROCEPT BioRobotics Corp.'s net margin of -12425.36%. PROCEPT BioRobotics Corp.'s return on equity of -23.51% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics Corp.62.87% -$0.38 $459.2M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About PRCT or CATX?
PROCEPT BioRobotics Corp. has a consensus price target of $50.73, signalling upside risk potential of 74.14%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 354.16%. Given that Perspective Therapeutics, Inc. has higher upside potential than PROCEPT BioRobotics Corp., analysts believe Perspective Therapeutics, Inc. is more attractive than PROCEPT BioRobotics Corp..
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics Corp.8 3 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is PRCT or CATX More Risky?
PROCEPT BioRobotics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock PRCT or CATX?
PROCEPT BioRobotics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics Corp. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or CATX?
PROCEPT BioRobotics Corp. quarterly revenues are $83.3M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. PROCEPT BioRobotics Corp.'s net income of -$21.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, PROCEPT BioRobotics Corp.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics Corp. is 5.34x versus 183.75x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics Corp.5.34x -- $83.3M -$21.4M CATXPerspective Therapeutics, Inc.183.75x -- $209K -$26M
-
Which has Higher Returns PRCT or INFU?
InfuSystem Holdings, Inc. has a net margin of -25.7% compared to PROCEPT BioRobotics Corp.'s net margin of 6.19%. PROCEPT BioRobotics Corp.'s return on equity of -23.51% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics Corp.62.87% -$0.38 $459.2M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About PRCT or INFU?
PROCEPT BioRobotics Corp. has a consensus price target of $50.73, signalling upside risk potential of 74.14%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 67.45%. Given that PROCEPT BioRobotics Corp. has higher upside potential than InfuSystem Holdings, Inc., analysts believe PROCEPT BioRobotics Corp. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics Corp.8 3 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is PRCT or INFU More Risky?
PROCEPT BioRobotics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock PRCT or INFU?
PROCEPT BioRobotics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics Corp. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or INFU?
PROCEPT BioRobotics Corp. quarterly revenues are $83.3M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. PROCEPT BioRobotics Corp.'s net income of -$21.4M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, PROCEPT BioRobotics Corp.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 32.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics Corp. is 5.34x versus 1.28x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics Corp.5.34x -- $83.3M -$21.4M INFUInfuSystem Holdings, Inc.1.28x 32.43x $36.5M $2.3M
-
Which has Higher Returns PRCT or VNRX?
VolitionRX Ltd. has a net margin of -25.7% compared to PROCEPT BioRobotics Corp.'s net margin of -862.39%. PROCEPT BioRobotics Corp.'s return on equity of -23.51% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics Corp.62.87% -$0.38 $459.2M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About PRCT or VNRX?
PROCEPT BioRobotics Corp. has a consensus price target of $50.73, signalling upside risk potential of 74.14%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 680.14%. Given that VolitionRX Ltd. has higher upside potential than PROCEPT BioRobotics Corp., analysts believe VolitionRX Ltd. is more attractive than PROCEPT BioRobotics Corp..
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics Corp.8 3 0 VNRXVolitionRX Ltd.4 2 0 -
Is PRCT or VNRX More Risky?
PROCEPT BioRobotics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock PRCT or VNRX?
PROCEPT BioRobotics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics Corp. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or VNRX?
PROCEPT BioRobotics Corp. quarterly revenues are $83.3M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. PROCEPT BioRobotics Corp.'s net income of -$21.4M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, PROCEPT BioRobotics Corp.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics Corp. is 5.34x versus 19.32x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics Corp.5.34x -- $83.3M -$21.4M VNRXVolitionRX Ltd.19.32x -- $627.3K -$5.4M
-
Which has Higher Returns PRCT or VTAK?
Catheter Precision, Inc. has a net margin of -25.7% compared to PROCEPT BioRobotics Corp.'s net margin of -1037.17%. PROCEPT BioRobotics Corp.'s return on equity of -23.51% beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics Corp.62.87% -$0.38 $459.2M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About PRCT or VTAK?
PROCEPT BioRobotics Corp. has a consensus price target of $50.73, signalling upside risk potential of 74.14%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1552.22%. Given that Catheter Precision, Inc. has higher upside potential than PROCEPT BioRobotics Corp., analysts believe Catheter Precision, Inc. is more attractive than PROCEPT BioRobotics Corp..
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics Corp.8 3 0 VTAKCatheter Precision, Inc.0 0 0 -
Is PRCT or VTAK More Risky?
PROCEPT BioRobotics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.
-
Which is a Better Dividend Stock PRCT or VTAK?
PROCEPT BioRobotics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics Corp. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or VTAK?
PROCEPT BioRobotics Corp. quarterly revenues are $83.3M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. PROCEPT BioRobotics Corp.'s net income of -$21.4M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, PROCEPT BioRobotics Corp.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics Corp. is 5.34x versus 10.81x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics Corp.5.34x -- $83.3M -$21.4M VTAKCatheter Precision, Inc.10.81x 0.40x $226K -$2.3M
-
Which has Higher Returns PRCT or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -25.7% compared to PROCEPT BioRobotics Corp.'s net margin of 3.93%. PROCEPT BioRobotics Corp.'s return on equity of -23.51% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics Corp.62.87% -$0.38 $459.2M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About PRCT or XTNT?
PROCEPT BioRobotics Corp. has a consensus price target of $50.73, signalling upside risk potential of 74.14%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 129.78%. Given that Xtant Medical Holdings, Inc. has higher upside potential than PROCEPT BioRobotics Corp., analysts believe Xtant Medical Holdings, Inc. is more attractive than PROCEPT BioRobotics Corp..
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics Corp.8 3 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is PRCT or XTNT More Risky?
PROCEPT BioRobotics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock PRCT or XTNT?
PROCEPT BioRobotics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics Corp. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or XTNT?
PROCEPT BioRobotics Corp. quarterly revenues are $83.3M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. PROCEPT BioRobotics Corp.'s net income of -$21.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, PROCEPT BioRobotics Corp.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 64.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics Corp. is 5.34x versus 0.71x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics Corp.5.34x -- $83.3M -$21.4M XTNTXtant Medical Holdings, Inc.0.71x 64.00x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did AMD Stock Go Up?
Since January 9th, shares of chipmaker AMD (NASDAQ:AMD) have been…
Will Data Centers Be In Space?
With demand for data centers seemingly growing by the day,…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
70
BNAI alert for Jan 26
Brand Engagement Network, Inc. [BNAI] is up 85.07% over the past day.
Buy
56
INTC alert for Jan 26
Intel Corp. [INTC] is down 5.61% over the past day.
Buy
64
BNR alert for Jan 26
Burning Rock Biotech Ltd. [BNR] is up 2.08% over the past day.
